EFFECT OF DAFLON (DIOSMIN AND HESPERIDIN) ON POST-OPERATIVE SEROMA FORMATION IN BREAST CANCER SURGERY''
seroma
2 other identifiers
interventional
190
1 country
1
Brief Summary
Post-operative seroma formation remains one of the most common complications following breast cancer surgery. This prospective randomized controlled trial was conducted to evaluate the efficacy of Micronized Purified Flavonoid Fraction (Daflon) in reducing post-operative seroma formation in patients undergoing breast cancer surgery with sentinel lymph node biopsy or axillary lymph node dissection.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for phase_4
Started Oct 2024
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
October 1, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
February 28, 2026
CompletedStudy Completion
Last participant's last visit for all outcomes
April 15, 2026
CompletedFirst Submitted
Initial submission to the registry
May 7, 2026
CompletedFirst Posted
Study publicly available on registry
May 15, 2026
CompletedMay 15, 2026
May 1, 2026
1.4 years
May 7, 2026
May 13, 2026
Conditions
Outcome Measures
Primary Outcomes (1)
post-operative seroma formation
reduction of post-operative seroma formation
8 weeks
Study Arms (2)
Intervention group
EXPERIMENTALControl group
NO INTERVENTIONControl group did not receive Daflon.
Interventions
Patients received Daflon 500 mg orally twice daily for four weeks after breast cancer surgery.
Eligibility Criteria
You may qualify if:
- \- Patients undergoing breast cancer surgery, including either breast-conserving surgery or mastectomy with sentinel lymph node biopsy (SLNB) or axillary lymph node dissection (ALND), during the study period were included
You may not qualify if:
- Patients were excluded if they had pre-existing disease-related upper limb lymphedema, had undergone extensive oncoplastic procedures such as latissimus dorsi myocutaneaous flap (LDMF) or deep inferior epigastric perforator (DIEP) flap reconstruction, had a previously irradiated breast, or underwent only wide local excision under local anaesthesia in the setting of American Society of Anaesthesiologists (ASA) class IV or higher.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Ittefaq Hospital Trust
Lahore, Punjab Province, 54000, Pakistan
Related Publications (1)
Calpin GG, McAnena PF, Davey MG, Calpin P, Kerin MJ, McInerney N, Walsh SR, Lowery AJ. The role of tranexamic acid in reducing post-operative bleeding and seroma formation in breast surgery: A meta-analysis. Surgeon. 2023 Aug;21(4):e183-e194. doi: 10.1016/j.surge.2022.11.005. Epub 2022 Dec 24.
PMID: 36572609BACKGROUND
MeSH Terms
Interventions
Intervention Hierarchy (Ancestors)
Study Design
- Study Type
- interventional
- Phase
- phase 4
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- PREVENTION
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Principal Investigator
Study Record Dates
First Submitted
May 7, 2026
First Posted
May 15, 2026
Study Start
October 1, 2024
Primary Completion
February 28, 2026
Study Completion
April 15, 2026
Last Updated
May 15, 2026
Record last verified: 2026-05
Data Sharing
- IPD Sharing
- Will not share
Individual participant data will not be publicly shared due to institutional data protection policies and participant confidentiality considerations